Preclinical News and Research

RSS

First human study of pioneering 'cell bandage' technology

A company co-founded by Professor Anthony Hollander has raised over £1.6 million to fund trials, including the first human study, of its pioneering 'cell bandage' technology, which aims to save thousands of patients from the type of knee surgery that currently leads to premature osteoarthritis.

22 Apr 2009

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.

22 Apr 2009

Potential new drug blocks pathway of deadliest cancer

Scientists at Cancer Research Technology Ltd (CRT) will present exciting new findings showing that a potent and selective inhibitor of protein kinase D called CRT0066101, inhibits the growth of pancreatic tumours.

20 Apr 2009

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

NanoBio has announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

20 Apr 2009

Humanized mouse infected with HIV vaginally and rectally allows testing

The "humanized mouse" developed by Dr. J. Victor Garcia-Martinez has allowed the University of Texas Southwestern physician-scientist to conduct HIV/AIDS studies that would have been impossible without such a small animal model of HIV infection.

20 Apr 2009

Overexpression of PEA-15 protein shrinks breast cancer tumors

Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.

20 Apr 2009

First compound for receptors in schizophrenia and Alzheimer's holds promise

For almost 20 years, pharmacological companies have known that certain compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer's disease (AD).

20 Apr 2009

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.

20 Apr 2009

Chemists synthesize natural alkaloid that could have anti-cancer properties

The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments.

15 Apr 2009

$Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma$

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

8 Apr 2009

Stem cells from bone marrow used to grow new blood vessels

Research led by David Hess of the Robarts Research Institute at The University of Western Ontario has identified how to use selected stem cells from bone marrow to grow new blood vessels to treat diseases such as peripheral artery disease.

6 Apr 2009

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals, Inc. has announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

6 Apr 2009

Nanobiotix reports 'proof of concept' for use of nanoparticles in treating glioblastoma multiforme

Nanobiotix has announced that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology.

6 Apr 2009

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

2 Apr 2009

FDA clears Cellectar's IND application for drug candidate

Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

2 Apr 2009

Preclinical News and Research

First human study of pioneering 'cell bandage' technology

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

Potential new drug blocks pathway of deadliest cancer

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

Humanized mouse infected with HIV vaginally and rectally allows testing

Overexpression of PEA-15 protein shrinks breast cancer tumors

First compound for receptors in schizophrenia and Alzheimer's holds promise

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Chemists synthesize natural alkaloid that could have anti-cancer properties

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Experimental drug lowers PSA levels

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Stem cells from bone marrow used to grow new blood vessels

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

Nanobiotix reports 'proof of concept' for use of nanoparticles in treating glioblastoma multiforme

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

FDA clears Cellectar's IND application for drug candidate

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Researchers develop mouse models of leukemia that predict response to chemotherapy

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News